Lophius augments its round of financing
Lophius Biosciences GmbH, a spin off from the University of Regensburg in 2002, has been developing and marketing innovative immune diagnostic systems to patients in the area of transplantation, infectious and autoimmune diseases. The additional capital is to fast-track in particular the development of novel tuberculosis diagnostics and drive the potential of the company's T cell and immunodiagnostic technology platform. Lophius has recently been able to conclude a "proof-of-concept" study for differential diagnosis of tuberculosis on the basis of its proprietary "reverse T cell technology" platform. The technology developed by Lophius enables the differentiation of patients with infectious active illness from persons with a latent infection. "As there is currently no effective tuberculosis vaccine available, diagnosis and treatment are the only available weapons to fight the disease. With more than 10 million new cases in 2015 and 1,7 billion people with latent infections worldwide, the Lophius solution is addressing a far-reaching undiscovered market demand", stated Bernd Merkl, CEO of Lophius Biosciences GmbH. T cells are white blood cells which serve the immune defense of the body.